Table 1 General characteristics of study participants (adjusted)
Characteristic | Â | Total | HBsAg(+) | HBsAb(+) | HBeAg(+) | HBeAb(+) | HBcAb(+) | Anti-HCV |
|---|---|---|---|---|---|---|---|---|
| Â | Population | %(95%CI) | %(95%CI) | %(95%CI) | %(95%CI) | %(95%CI) | %(95%CI) | |
Total number | Adjusted rate | 6541 | 3.8(3.33, 4.26) | 55.2(54.0, 56.4) | 0.72(0.52, 0.92) | 14.9(14.0.6, 15.8) | 60.9(59.7, 62.1) | 0.36(0.21, 0.50) |
Gender | ||||||||
| Â | Male | 3281 | 4.58(3.86, 5.30) | 55.4(53.7, 57.1) | 0.92(0.59, 1.25) | 14.9(13.68, 16.12) | 59.8(58.1, 61.5) | 0.43(0.12, 0.65) |
Female | 3260 | 3.0(2.41, 3.59) | 54.9(53.2, 56.6) | 0.51(0.27, 0.75) | 14.8(13.62, 16.06) | 61.9(60.3, 63.6) | 0.33(0.13, 0.53) | |
Age (years) | ||||||||
|  | < 1 | 382 | 0.0(0, 0) | 84.8(81.2, 88.4) | 0.0(0, 0) | 8.9(6.0, 11.8) | 75.1(70.8, 79.4) | 0(0,0) |
1–4 | 1614 | 0.2(0, 0.42) | 60.7(58.3, 63.1) | 0.1(0, 0.25) | 8.6(7.2, 10.0) | 71.7(69.5, 73.9) | 0.3(0.03, 0.57) | |
5–14 | 1413 | 0.2(0, 0.43) | 53.0(50.4, 55.6) | 0.1(0, 0.26) | 6.3(5.0, 7.6) | 60.7(58.2, 63.2) | 0.1(0, 0.26) | |
15–29 | 1808 | 2.9(2.1, 3.7) | 62.9(60.7, 65.1) | 0.7(0.32, 1.10) | 12.3(10.8, 13.8) | 57.5 (55.2, 59.8) | 0.4(0.1, 0.7) | |
30–39 | 502 | 4.4(2.6,6.2) | 53.6(49.2,58.0) | 1.2 (0.25, 2.2) | 14.5(11.4,17.6) | 59.6(55.3,63.9) | 0(0,0) | |
40–49 | 455 | 5.9(3.73,8.07) | 49.5(44.9,54.1) | 0.9(0.03,1.77) | 17.4(13.9,20.9) | 62.9(58.5,67.3) | 0.2(0,0.61) | |
50–59 | 367 | 4.9(2.7,7.1) | 49.0(43.9,54.1) | 0.5(0,1.2) | 23.4(19.1,27.7) | 63.2(58.3,68.1) | 1.1(0.03, 2.2) | |
HBV vaccination | ||||||||
| Â | Yes | 4289 | 37(0.9) | 2681(62.5) | 13(0.3) | 361(8.4) | 2846(66.4) | 9(0.2) |
No | 961 | 42(4.4) | 468(48.7) | 7(0.7) | 169(17.6) | 544(56.6) | 2(0.2) | |
Unclear | 1291 | 48(3.7) | 714(55.3) | 8(0.6) | 191(14.8) | 768(59.5) | 9(0.7) | |